The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: A 2-year trial

Londen, G J. Van; Perera, Subashan; Vujevich, Karen T.; Sereika, Susan M.; Bhattacharya, Rajib; Greenspan, Susan L.

doi:10.1016/j.bone.2009.10.019

Cited by 11 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(23) Recent studies have also examined the effectiveness of the oral bisphosphonate risedronate in limiting postmenopausal AI-induced bone loss, and concluded that once-weekly risedronate leads to maintenance of skeletal structural integrity(24) and increases in lumbar spine and hip BMD compared to placebo, an effect most pronounced in women with lower T-scores at baseline. (25, 26)…”

Section: Breast Cancermentioning

confidence: 99%

Osteoporosis and Cancer

Drake

2013

Curr Osteoporos Rep

View full text Add to dashboard Cite

Cancer is a major risk factor for bone loss and fractures. This is due both to direct effects of cancer cells on the skeleton and to deleterious effects of cancer-specific therapies on bone cells. Marked improvements in survival for many cancers mean that strategies to limit bone loss and reduce fracture risk must be incorporated into the care plans for nearly all patients with cancer. The vast majority of effort thus far has focused on bone loss in patients with breast and prostate cancers, with comparatively few studies in other malignancies. Anti-resorptive therapies have proven nearly universally effective for limiting bone loss in cancer patients, although few studies have been powered sufficiently to include fractures as primary endpoints, and patients are frequently neither identified nor treated according to published guidelines. Non-pharmacologic approaches to limit falls, particularly in elderly patients, are also likely important adjunctive measures for most cancer patients.

show abstract